Wisevoter
U.S.

Moderna Shares Have Surged 663 Percent in 2026

The company's stock rallied after a successful cancer vaccine trial and its return to the Nasdaq-100 index.

Updated on Oct. 10, 2026 in Stock Markets

Isometric editorial illustration of a metallic DNA lattice structure, representing scientific growth in the biotech sector.
Moderna shares surged 663 percent in 2026, bolstered by successful final-stage cancer vaccine trials and mandatory inclusion in the Nasdaq-100 index. AI Illustration. Upload story photo >

Live Poll

Is now a good time to invest in companies experiencing major stock price volatility?

Moderna shares closed at $225 on October 9, 2026, marking a 663 percent increase for the year. This dramatic growth was driven by positive results from a final-stage cancer vaccine trial and mandatory buying from index-tracking funds.

Why it matters

The surge reflects massive investor optimism surrounding the company's experimental cancer vaccine, which outperformed expectations during final-stage testing. Meanwhile, the inclusion of Moderna in the Nasdaq-100 has forced institutional buying, further inflating its market value.

Moderna now carries a market capitalization of $89.8 billion following its 663 percent YTD increase. Over 200 funds tracking the Nasdaq-100, which hold more than $800 billion in assets, have increased their positions in the firm.

The players

Moderna

This biotechnology company focuses on messenger RNA therapeutics and vaccines.

Merck

This multinational pharmaceutical corporation collaborated with Moderna on the cancer vaccine trial.

Martin Shkreli

This former hedge fund manager and pharmaceutical executive is a prominent commentator on biotech stocks.

The details

Moderna's resurgence follows a difficult 2025 where the company cut more than 800 jobs. Shares briefly jumped 177 percent on August 19, 2026, following the cancer vaccine trial news, before dropping 24 percent the next day as traders took profits.

Timeline

  1. Moderna reduced its workforce by more than 800 jobs in 2025.

  2. Stock prices rose 125 percent by June 2026.

  3. A cancer vaccine trial passed its final stage on August 19, 2026.

  4. Moderna shares finished at $225 on October 9, 2026.

  5. Full clinical trial results are expected on October 24, 2026.

Market Dynamics

This story follows a pattern established by the Nasdaq-100 index where institutional fund rebalancing forces rapid price adjustments for newly added companies. The stock's volatile performance reflects broader sector shifts toward AI-driven data centers and high-stakes clinical breakthroughs.

Retail investors should note that the stock's high volatility, highlighted by the 24 percent single-day drop in August, poses significant risks for those holding positions. Market analysts like Martin Shkreli have projected that the current price bubble may face a correction within six months.

The takeaway

While clinical trial successes provide momentum for biotech stocks, investors should remain cautious of volatility driven by index inclusion and speculative rallies. Always evaluate whether a share price increase is supported by long-term clinical data or simply technical fund rebalancing.

What happens next

Full results for the cancer vaccine trial are expected to be released on October 24, 2026, followed by a potential national vaccine program in December 2026.

Further reading

For more on the current climate of public equities, see our Stock Markets section.

Source note: This article includes information reported by BeInCrypto.

Live Poll

Is now a good time to invest in companies experiencing major stock price volatility?